Assignee
MINORYX THERAPEUTICS S L
ES·9 granted patents·7 pending applications·16 citations·filing 2014–2024
Top patents by PatentIndex Score
16 records- 0189US9782395B22,4-thiazolidinedione derivatives in the treatment of central nervous system disordersMINORYX THERAPEUTICS S L·Filed 2016·Granted Oct 10, 2017·13 cites·22 claims
- 0277US10179126B22,4-thiazolidinedione derivatives in the treatment of central nervous system disordersMINORYX THERAPEUTICS S L·Filed 2017·Granted Jan 15, 2019·2 cites·26 claims
- 0373US11124505B2Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereofMINORYX THERAPEUTICS S L·Filed 2017·Granted Sep 21, 2021·1 cites·63 claims
- 0469US2025064791A15-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseasesMINORYX THERAPEUTICS S L·Filed 2024·Application pending·0 cites
- 0568US2024091210A1Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its saltsMINORYX THERAPEUTICS S L·Filed 2023·Application pending·0 cites
- 0665US11731963B2Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereofMINORYX THERAPEUTICS S L·Filed 2021·Granted Aug 22, 2023·0 cites·18 claims
- 0756US11739072B2Heteroaryl compounds and their useMINORYX THERAPEUTICS S L·Filed 2021·Granted Aug 29, 2023·0 cites·30 claims
- 0855US11938122B25-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver diseaseMINORYX THERAPEUTICS S L·Filed 2017·Granted Mar 26, 2024·0 cites·13 claims
- 0953US2019255032A12,4-Thiazolidinedione Derivatives in the Treatment of Central Nervous System DisordersMINORYX THERAPEUTICS S L·Filed 2018·Application pending·0 cites
- 1052US11957670B25-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseasesMINORYX THERAPEUTICS S L·Filed 2019·Granted Apr 16, 2024·0 cites·18 claims
- 1150US2021228558A1Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its saltsMINORYX THERAPEUTICS S L·Filed 2019·Application pending·0 cites
- 1248US2021308113A1Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dioneMINORYX THERAPEUTICS S L·Filed 2019·Application pending·0 cites
- 1348US2023172921A1Leriglitazone for treating lung inflammation and interstitial lung diseaseMINORYX THERAPEUTICS S L·Filed 2021·Application pending·0 cites
- 1441US11174242B2Heteroaryl compounds and their useMINORYX THERAPEUTICS S L·Filed 2017·Granted Nov 16, 2021·0 cites·28 claims
- 1538US2016168132A1Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereofMINORYX THERAPEUTICS S L·Filed 2014·Application pending·0 cites
- 1636US11440898B2Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidaseMINORYX THERAPEUTICS S L·Filed 2017·Granted Sep 13, 2022·0 cites·23 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →